Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

British Journal of Cancer

Volumn 110, Issue 9, 2014, Pages 2165-2169

  Fornaro, L ^a   Cereda, S ^b   Aprile, G ^c   Di Girolamo, S ^d   Santini, D ^e   Silvestris, N ^f   Lonardi, S ^g   Leone, F ^h   Milella, M ⁱ   Vivaldi, C ^j   Belli, C ^b   Bergamo, F ^g   Lutrino, S E ^c   Filippi, R ^h   Russano, M ^e   Vaccaro, V ⁱ   Brunetti, A E ^f   Rotella, V ^a   Falcone, A ^j   Barbera, M A ^d   Corbelli, J ^d   Fasola, G ^c   Aglietta, M ^h   Zagonel, V ^g   Reni, M ^b   Vasile, E ^j   Brandi, G ^d   more..

^a Division of Medical Oncology Azienda USL2 Lucca   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY HOSPITAL OF PISA   (Italy)

more..

Author keywords

advanced biliary tract cancer; chemotherapy; prognostic factors; second line

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CANCER; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL PRACTICE; CONFIDENCE INTERVAL; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PATIENT HISTORY OF SURGERY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; STRATIFICATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84899903660     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.190     Document Type: Article

References (15)

1. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C. GERCOR Group (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15(9): 1339-1343.
2. Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J (2013) Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 49(6): 1511.
3. Cereda S, Belli C, Rognone A, Mazza E, Reni M (2013) Second-line therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol 88(2): 368-374.
4. Charbel H, Al-Kawas FH (2011) Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep 13(2): 182-187.
5. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341(18): 1368-1378.
6. Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F (2012) Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreatic Sci 19(4): 337-341.
7. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7(6): 593-600.
8. Lee SC, Kim K, Kim H, Kim HJ, Kim SH, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Won JH, Yun J, Hong DS, Park HS (2012) Prognostic factor analysis of second-line chemotherapy in advanced biliary tract cancer. J Clin Oncol 30: abstr e14688.
9. Marino D, Leone F, Cavalloni G, Cagnazzo C, Aglietta M (2013) Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol Hematol 85(2): 136-148.
10. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. Br J Cancer 103(4): 469-474.
11. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH (2009) Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 115(18): 4148-4155.
12. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP (2010) Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28(30): 4581-4586.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatement in solid tumors. EORTC, NCI USA, NCI Canada. J Natl Cancer Inst 92(3): 205-216.
14. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14): 1273-1281.
15. Walter T, Horgan AM, McNamara M, McKeever L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H, Feld R, Moore M, Knox JJ (2013) Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 49(2): 329-335.